|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
|
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net loss | ||||
| Interest earned on marketable securities held in Trust Account | ||||
| Change in fair value of Convertible Promissory Note – related party | ||||
| Net income (loss) | ||||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Depreciation and amortization | ||||
| Non-cash interest expense | ||||
| Non-cash vendor payments | ||||
| Change in allowance for doubtful accounts | ||||
| Loss on issuance of forward purchase agreement derivative liability | ||||
| Change in fair value of senior notes | ||||
| Loss on issuance of senior secured notes | ||||
| Change in fair value of forward purchase agreement derivative liability | ||||
| Stock-based compensation | ||||
| Non-cash lease expense | ||||
| Loss on extinguishment of senior secured | ||||
| Gain on extinguishment of forward purchase agreement settlement liability | ||||
| Gain on extinguishment of liabilities | ||||
| Gain on forbearance agreement | ||||
| Equity line of credit commitment expense | ||||
| Loss on fixed assets disposal | ||||
| Loss on extinguishment of senior notes | ||||
| Changes in operating assets and liabilities: | ||||
| Accounts receivable | ||||
| Prepaid expenses and other current and non-current assets | ||||
| Prepaid insurance, long-term | ||||
| Accrued expenses | ||||
| Accrued interest payable | ||||
| Deferred legal fee payable | ||||
| Accounts payable | ||||
| Accrued expenses and other current liabilities and other non-current liabilities | ||||
| Deferred revenue | ||||
| Deferred legal fees | ||||
| Forward purchase agreement settlement obligation | ||||
| Operating lease liabilities | ||||
| Net cash used in operating activities | ||||
| Cash flows from investing activities: | ||||
| Investment of cash into Trust Account | ||||
| Purchases of property and equipment | ||||
| Net cash used in investing activities | ||||
| Cash flows from financing activities: | ||||
| Proceeds from issuance of Class B ordinary shares to Anchor Investor | ||||
| Proceeds from sale of Units, net of underwriting discounts paid | ||||
| Proceeds from sale of Private Placement Warrants | ||||
| Payment of deferred offering costs | ||||
| Proceeds from the exercise of stock options | ||||
| Issuances of Common Stock under equity line of credit | ||||
| Proceeds from the reverse recapitalization | ||||
| Proceeds from the partial early termination of the forward purchase agreement | ||||
| Proceeds from note payable - related party | ||||
| Proceeds from convertible promissory note - related party | ||||
| Redemption of ordinary shares | ||||
| Prepayment for forward purchase agreement | ||||
| Debt discount paid in cash | ||||
| Proceeds from senior and senior secured notes | ||||
| Payment of senior secured notes | ||||
| Proceeds from convertible notes, net | ||||
| Proceeds from sale of Series A preferred stock, net | ||||
| Net cash provided by financing activities | ||||
| Effect of exchange rate changes on cash and cash equivalents | ||||
| Net increase (decrease) in cash and cash equivalents | ||||
| Cash and cash equivalents and restricted cash at beginning of period | ||||
| Cash and cash equivalents and restricted cash at end of period | ||||
| Remeasurement of Class A ordinary shares to redemption amount | ||||
| Proceeds received from convertible promissory notes in excess of initial fair value | ||||
| Offering costs accrued | ||||
| Excess fair value of Founder shares attributable to Anchor Investor | ||||
| Accretion for Class A ordinary shares to redemption amount | ||||
| Deferred underwriting fee payable | ||||
| Supplemental disclosures | ||||
| Debt conversion, aggregate amount | ||||
| Issuance of Common Stock in connection with debt issuance costs related to senior secured notes and capital markets advisory agreements | ||||
| Issuance of senior secured notes in lieu of payments for offering costs and capital markets advisory agreements | ||||
| Deferred offering costs included in accounts payable and accrued expenses and other current liabilities | ||||
| Debt issuance costs in included in accrued expenses and other current liabilities | ||||
| Conversion of convertible preferred stock upon the reverse recapitalization | ||||
| Issuance of Common Stock under the 2024 Equity and Incentive Plan | ||||
| Purchases of property and equipment included in accounts payable and accrued expenses | ||||
| Liabilities assumed from the merger | ||||
| Issuance of Common Stock in connection with settlement of liability | ||||
| Issuance of Common Stock in connection with settlement of forward purchase obligation | ||||
| Issuance of Common Stock upon conversion of related party notes | ||||
| Issuance of series C preferred stock in connection with settlement of liability | ||||
Loading...